145 related articles for article (PubMed ID: 8842923)
21. Susceptibilities of 97 strains of Xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors.
Ismaeel NA
Microbios; 1997; 91(367):97-103. PubMed ID: 9467924
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
Qadri SM; Ueno Y; Cunha BA
Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
[TBL] [Abstract][Full Text] [Related]
23. New drugs for treating lung infection.
Nolan PE; Bass JB
Chest; 1988 Nov; 94(5):1076-9. PubMed ID: 3053059
[No Abstract] [Full Text] [Related]
24. Evolution of beta-lactamase inhibitors.
Rolinson GN
Rev Infect Dis; 1991; 13 Suppl 9():S727-32. PubMed ID: 1656513
[TBL] [Abstract][Full Text] [Related]
25. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
26. [In vitro activity of beta-lactam agents and beta-lactamase inhibitors in clinical isolates of Acinetobacter baumannii].
López-Hernández S; Alarcón T; Delgado T; de Las Cuevas MC; López-Brea M
Rev Esp Quimioter; 1999 Jun; 12(2):140-3. PubMed ID: 10562675
[TBL] [Abstract][Full Text] [Related]
27. Newer beta-lactam agents and the Bacteroides fragilis group.
Cuchural GJ
Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
[TBL] [Abstract][Full Text] [Related]
28. Lipopolysaccharide alterations responsible for combined quinolone and beta-lactam resistance in Pseudomonas aeruginosa.
Leying HJ; Büscher KH; Cullmann W; Then RL
Chemotherapy; 1992; 38(2):82-91. PubMed ID: 1591950
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase.
Li C; Nicolau DP; Lister PD; Quintiliani R; Nightingale CH
J Antimicrob Chemother; 2004 Feb; 53(2):297-304. PubMed ID: 14729755
[TBL] [Abstract][Full Text] [Related]
30. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
31. New β-lactam antibiotics and β-lactamase inhibitors.
Bush K; Macielag MJ
Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
[TBL] [Abstract][Full Text] [Related]
32. Clinical trials of extended spectrum penicillin/beta-lactamase inhibitors in the treatment of intra-abdominal infections. European and North American experience.
Wilson SE; Nord CE
Am J Surg; 1995 May; 169(5A Suppl):21S-26S. PubMed ID: 7755164
[TBL] [Abstract][Full Text] [Related]
33. New Delhi metallo-β-lactamase (NDM-1): an update.
Shakil S; Azhar EI; Tabrez S; Kamal MA; Jabir NR; Abuzenadah AM; Damanhouri GA; Alam Q
J Chemother; 2011 Oct; 23(5):263-5. PubMed ID: 22005056
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
Jones RN; Pfaller MA; Doern GV; Erwin ME; Hollis RJ
Diagn Microbiol Infect Dis; 1998 Mar; 30(3):215-28. PubMed ID: 9572029
[TBL] [Abstract][Full Text] [Related]
35. In vitro stepwise selection of resistance to quinolones, beta-lactams and amikacin in nosocomial gram-negative bacilli.
Michéa-Hamzehpour M; Kahr A; Pechère JC
Infection; 1994; 22 Suppl 2():S105-10. PubMed ID: 7927828
[TBL] [Abstract][Full Text] [Related]
36. Beta-lactamase inhibitors: the story so far.
Pérez-Llarena FJ; Bou G
Curr Med Chem; 2009; 16(28):3740-65. PubMed ID: 19747143
[TBL] [Abstract][Full Text] [Related]
37. Double-disk synergy test positivity in Stenotrophomonas maltophilia clinical strains.
Hejnar P; Kolár M; Chmela Z
Folia Microbiol (Praha); 2004; 49(1):71-4. PubMed ID: 15114869
[TBL] [Abstract][Full Text] [Related]
38. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
[TBL] [Abstract][Full Text] [Related]
39. [Beta-lactamase inhibitors].
Launay O; Joly-Guillou ML; Decré D; Crémieux AC
Presse Med; 1997 Mar; 26(10):485-92. PubMed ID: 9137377
[TBL] [Abstract][Full Text] [Related]
40. In vitro activities of 36 antimicrobial agents against clinically isolated Bacteroides fragilis.
Teng LJ; Ho SW; Chang SC; Luh KT; Hsieh WC
J Formos Med Assoc; 1991 Aug; 90(8):796-9. PubMed ID: 1683376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
